Sunday 11 October 2026 Export all EQ data to Excel Powerpack

Equillium, Inc.

EQ Healthcare Biotechnology

Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.

1.41 0.03 −2.08%
Market cap
$91.3M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
−6.75
Beneish M
n/a
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Net Income

+8 more quarters

(4.23) (3.77) (5.31) (4.69)
Operating Cash Flow
(8.43) (3.13) (4.30) (4.11)
Investing cash flow
0.00 (0.03) 0.00 (0.07)
Financing cash flow
30.07 0.28 35.35 0.04
Ending Cash
21.63 (2.84) 61.32 (4.16)

Show all line items

In millions of $ except per-share values · columns are period end dates